Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject ...
Pharmabiz14h
Eupraxia Pharma reports positive data from RESOLVE phase 1b/2a trial of EP-104GI for treatment of eosinophilic esophagitis
Victoria, British Columbia Thursday, November 14, 2024, 18:00 Hrs [IST] ...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Overwhelming shareholder support in favour of take-private transaction with AditxtStudies presented at IDWeek 2024™ demonstrate ATI-1701 provides ...
TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. ( NASDAQ: TLSI) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & ...
News Medical on MSN15h
Study identifies a potential treatment for Sandhoff and Tay-Sachs diseases
In a groundbreaking study, researchers at McMaster University have identified a potential treatment for Sandhoff and Tay-Sachs diseases—two rare, often fatal lysosomal storage disorders that cause ...
The American Journal of Managed Care3h
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase ...
Weight-loss drugs replacing some surgeries, but doctors say they're 'not a miracle drug'
Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...